BETTER THERAPEUTICS INC (BTTX) Stock Price, Quote, News and Overview
NASDAQ:BTTX - Nasdaq - US08773T1043 - Common Stock - Currency: USD
BTTX Quote, Performance and Key Statistics
0.0446
+0.01 (+27.43%)
The current stock price of BTTX is 0.0446 USD. In the past month the price decreased by -78.14%. In the past year, price decreased by -95.79%.
BTTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 36.13 | 36.66B | ||
| DOCS | DOXIMITY INC-CLASS A | 56.54 | 13.58B | ||
| WAY | WAYSTAR HOLDING CORP | N/A | 7.26B | ||
| CERT | CERTARA INC | 33.77 | 2.12B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.98B | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 15.03 | 1.83B | ||
| SDGR | SCHRODINGER INC | N/A | 1.65B | ||
| PHR | PHREESIA INC | N/A | 1.64B | ||
| EVH | EVOLENT HEALTH INC - A | 15.8 | 1.22B | ||
| HSTM | HEALTHSTREAM INC | 50.58 | 999.88M | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 966.46M | ||
| DH | DEFINITIVE HEALTHCARE CORP | 14.47 | 762.50M |
Related stock screener links
About BTTX
Company Profile
Better Therapeutics, Inc. operates as a digital therapeutics company, which engages in developing a novel form of cognitive behavioral therapy to address the root causes of cardio metabolic diseases. The company is headquartered in San Francisco, California and currently employs 54 full-time employees. The company went IPO on 2021-01-08. The firm is engaged in developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases. Its lead PDT product candidate, BT-001, is an investigational prescription digital therapy for the treatment of T2D. The investigational therapy is delivered via software that provides a tailored experience to patients designed to help them address the underlying causes of T2D by making meaningful, sustainable behavioral changes. The BT-001 investigational therapy is rooted in the well-studied, gold standard of behavioral modification therapies, cognitive behavioral therapy (CBT). The firm's platform consists of three behavioral therapy, treatment plans and personalization. Its behavioral therapy consists of lessons, skill- building modules, and a mechanism for goal setting. Its treatment plan is the primary engagement interface for patients.
Company Info
BETTER THERAPEUTICS INC
548 Market St. #49404
San Francisco CALIFORNIA US
CEO: Suying Liu
Employees: 54
Company Website: https://www.bettertx.com/
Phone: 14158872311
BETTER THERAPEUTICS INC / BTTX FAQ
What is the stock price of BETTER THERAPEUTICS INC today?
The current stock price of BTTX is 0.0446 USD. The price increased by 27.43% in the last trading session.
What is the ticker symbol for BETTER THERAPEUTICS INC stock?
The exchange symbol of BETTER THERAPEUTICS INC is BTTX and it is listed on the Nasdaq exchange.
On which exchange is BTTX stock listed?
BTTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BETTER THERAPEUTICS INC stock?
8 analysts have analysed BTTX and the average price target is 5.36 USD. This implies a price increase of 11906.73% is expected in the next year compared to the current price of 0.0446. Check the BETTER THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BETTER THERAPEUTICS INC worth?
BETTER THERAPEUTICS INC (BTTX) has a market capitalization of 2.22M USD. This makes BTTX a Nano Cap stock.
How many employees does BETTER THERAPEUTICS INC have?
BETTER THERAPEUTICS INC (BTTX) currently has 54 employees.
Is BETTER THERAPEUTICS INC (BTTX) expected to grow?
The Revenue of BETTER THERAPEUTICS INC (BTTX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the BTTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BETTER THERAPEUTICS INC (BTTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BTTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BTTX, evaluating the profitability, health, valuation and growth aspects
- BETTER THERAPEUTICS INC (BTTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BETTER THERAPEUTICS INC (BTTX) Sales and EPS estimates to see what analysts future expectations are.
- BETTER THERAPEUTICS INC (BTTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BETTER THERAPEUTICS INC (BTTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- BETTER THERAPEUTICS INC (BTTX) Stock Chart to make your own analysis
- BETTER THERAPEUTICS INC (BTTX) Latest news and press-releases to stay up to date.
Does BETTER THERAPEUTICS INC (BTTX) stock pay dividends?
BTTX does not pay a dividend.
When does BETTER THERAPEUTICS INC (BTTX) report earnings?
BETTER THERAPEUTICS INC (BTTX) will report earnings on 2024-03-27, after the market close.
What is the Price/Earnings (PE) ratio of BETTER THERAPEUTICS INC (BTTX)?
BETTER THERAPEUTICS INC (BTTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.15).
What is the Short Interest ratio of BETTER THERAPEUTICS INC (BTTX) stock?
The outstanding short interest for BETTER THERAPEUTICS INC (BTTX) is 0% of its float. Check the ownership tab for more information on the BTTX short interest.
BTTX Technical Analysis
BTTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BTTX. Both the profitability and financial health of BTTX have multiple concerns.
BTTX Financial Highlights
Over the last trailing twelve months BTTX reported a non-GAAP Earnings per Share(EPS) of -1.15. The EPS increased by 43.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -294.55% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BTTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to BTTX. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 50.82% and a revenue growth -100% for BTTX